DPP4 and Parkinson disease: However, this is significantly reduced in those patients taking incretin mimetics or DPP-4 inhibitors [64, 65] in line with our administration of gliptins prior to 6-OHDA unilateral lesion mitigating ensuing PD-associated effects in our pretreatment animal model.